Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

Positive liver data for GKT831
August 2019
SHARING OPTIONS:

ARCHAMPS, France—July saw biopharmaceutical company Genkyotex announce the publication of data regarding GKT831 in Clinics and Research in Hepatology and Gastroenterology. The data showed that GKT831 is capable of preventing multiple complications of portal hypertension in a preclinical model. Portal hypertension is a major complication of cirrhosis that develops when advanced liver cirrhosis impedes hepatic blood flow, which leads to a cascade of downstream issues. GKT831 administration was shown to prevent the development of issues such as splanchnic angiogenesis, cardiac overload and portal-systemic shunting. Additionally, inhibition of NOX1/4 by GKT831 targeted multiple pathways and pathogenic processes associated with progressive liver disease. In a Phase 2 trial in primary biliary cholangitis, GKT831 led to reduced liver stiffness (which is tied to liver fibrosis) and was generally safe and well tolerated at all doses.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.